ArticleAlimentary pharmacology & therapeutics2026
Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03267615 (VICIS - Vienna Cirrhosis Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VICIS - Vienna Cirrhosis Study
Who cites it
1 citing paper in PubMed.
- Functional liver imaging score (FLIS): A prognostic biomarker for acute-on-chronic liver failure and liver-related mortality.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundIndocyanine green (ICG) clearance, determined by venous sampling, has shown promising results in the diagnosis of clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) and prognostication in decompensated ACLD (decompensated cirrhosis). Data on ICG clearance measurement by pulse dye densitometry (PDD) via finger clip are comparatively scarce.
aimsTo evaluate the diagnostic (CSPH) and prognostic utility of ICG clearance throughout ACLD stages.
methodsACLD (liver stiffness ≥ 10 kPa) patients undergoing same-day hepatic venous pressure gradient (HVPG) measurement and ICG clearance assessment via PDD in 2017-2022 were recruited from the prospective Vienna Cirrhosis Study (VICIS, NCT03267615).
resultsTwo hundred and sixty-one ACLD patients (cACLD: n = 115, decompensated cirrhosis: n = 146) were included. Among cACLD patients (CSPH: 62.4%), ICG retention 15 min (ICG-R15) correlated moderately with HVPG (Spearman's rho:0.458; p < 0.001) and yielded a suboptimal diagnostic accuracy for CSPH (AUROC: 0.687 [95% CI: 0.585-0.789]). ICG-R15 showed a strong correlation with the model for end-stage liver disease score (rho: 0.701; p < 0.001) and correlated with biomarkers of endothelial dysfunction (von Willebrand factor), systemic inflammation (C-reactive protein, procalcitonin, interleukin 6) and extracellular matrix remodelling (enhanced liver fibrosis test). In decompensated cirrhosis, ICG-R15 additionally correlated with mean arterial pressure, serum sodium and renin levels. ICG-R15 predicted decompensation (subdistribution hazard ratio [SHR]: 1.042 [95% CI: 1.008-1.077] per %; p = 0.014) in cACLD and independently predicted ACLF/liver-related mortality in decompensated cirrhosis (adjusted SHR: 1.062 [95% CI: 1.025-1.100] per %; p < 0.001).
conclusionsICG-R15 by PDD correlates with portal hypertension and systemic inflammation/circulatory dysfunction as key disease-driving mechanisms in ACLD. While showing insufficient discrimination for CSPH, ICG-R15 independently predicted ACLF/liver-related mortality in decompensated cirrhosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.